{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RA&page=2", "query": { "condition": "RA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T19:46:56.346Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000435", "title": "dnaJ Peptide for Relieving Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "dnaJ peptide", "type": "DRUG" }, { "name": "None-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 160, "start_date": "1999-09", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2007-07-31", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 8, "location_summary": "Tucson, Arizona • Orange, California • Palo Alto, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000435" }, { "nct_id": "NCT06671054", "title": "A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "AP1189, 40 mg", "type": "DRUG" }, { "name": "AP1189, 70 mg", "type": "DRUG" }, { "name": "AP1189, 100 mg", "type": "DRUG" }, { "name": "AP1189 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SynAct Pharma Aps", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2024-10-01", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 3, "location_summary": "Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania", "locations": [ { "city": "Cutler Bay", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Duncansville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06671054" }, { "nct_id": "NCT00458159", "title": "A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "CC-11006", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-05-01", "completion_date": "2008-12-01", "has_results": false, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 7, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Bethesda, Maryland + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458159" }, { "nct_id": "NCT07607964", "title": "A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Rheumatoid Arthritis" ], "interventions": [ { "name": "ABBV-519", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2026-05-28", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 5, "location_summary": "Los Angeles, California • Tustin, California • Greenacres City, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Greenacres City", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Red Oak", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07607964" }, { "nct_id": "NCT04474392", "title": "Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "N/A (Observational Study)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 340, "start_date": "2020-08-01", "completion_date": "2025-07-14", "has_results": false, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04474392" }, { "nct_id": "NCT02714881", "title": "Lipids, Inflammation, and CV Risk in RA", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Cardiovascular Disease" ], "interventions": [ { "name": "Certolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "35 Years to 90 Years" }, "enrollment_count": 74, "start_date": "2016-10-17", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02714881" }, { "nct_id": "NCT04862858", "title": "Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2", "Cardiovascular Diseases" ], "interventions": [ { "name": "Educational Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Humana Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 4197, "start_date": "2021-08-18", "completion_date": "2022-08-16", "has_results": false, "last_update_posted_date": "2022-05-20", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04862858" }, { "nct_id": "NCT02873936", "title": "Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "csDMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 449, "start_date": "2016-07-27", "completion_date": "2018-06-26", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 55, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Hemet", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02873936" }, { "nct_id": "NCT01776398", "title": "Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)", "Smoking", "Smoking Cessation", "Idiopathic Pulmonary Fibrosis (IPF)", "Rheumatoid Arthritis-Associated Interstitial Lung Disease", "Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)" ], "interventions": [], "intervention_types": [], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2012-08-29", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01776398" }, { "nct_id": "NCT06293365", "title": "Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjögrens Disease", "Systemic Lupus Erythematosus", "Rheumatoid Arthritis" ], "interventions": [ { "name": "VAY736 1ml PFS", "type": "BIOLOGICAL" }, { "name": "VAY736 2 ml PFS", "type": "BIOLOGICAL" }, { "name": "VAY736 2ml AI", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 155, "start_date": "2024-07-02", "completion_date": "2029-01-16", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-10T19:46:56.346Z", "location_count": 17, "location_summary": "Anniston, Alabama • Fullerton, California • La Palma, California + 14 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Lawrenceville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06293365" } ] }